双联抗血小板治疗启动时机与轻型卒中或高危TIA疗效
DAPT组主要复合结局风险低于单药组(HR 0.82,95%CI 0.77-0.87),24小时内启动获益最显著(HR 0.74,95%CI 0.69-0.79),24至72小时启动无显著获益,超过72小时启动风险可能升高。
要点
- 轻型卒中或高危TIA患者24小时内启动DAPT获益最显著。
- 24至72小时启动DAPT未观察到显著获益。
- 超过72小时启动DAPT可能增加风险,阈值约42小时。
核心结论
- 早期启动DAPT与最大临床获益相关,符合现行指南推荐。
- 超过24小时后疗效逐渐下降,估算阈值约42小时。
研究设计与样本
- 前瞻性多中心队列研究,纳入20家卒中中心2011年1月至2023年4月就诊患者。
- 比较院内启动DAPT与单药(阿司匹林或氯吡格雷)治疗,按发病至到院时间分组分析。
主要发现
- DAPT组90天主要复合结局发生率10.7%(2663例),单药组11.6%(1900例),HR 0.82(95%CI 0.77-0.87)。
- 24小时内启动DAPT的HR为0.74(95%CI 0.69-0.79)。
- 24至72小时启动DAPT的HR为1.00(95%CI 0.88-1.15)。
- 超过72小时启动DAPT的HR为1.25(95%CI 1.01-1.55)。
- 时间依赖分析显示获益在约42小时跨过无效线。
关键数值与推荐
- 主要结局为90天内复发性卒中、心肌梗死和死亡的复合终点。
- DAPT组90天主要结局10.7%,单药组11.6%,HR 0.82(95%CI 0.77-0.87)。
- 24小时内启动DAPT的HR 0.74(95%CI 0.69-0.79)。
- 24至72小时启动DAPT的HR 1.00(95%CI 0.88-1.15)。
- 超过72小时启动DAPT的HR 1.25(95%CI 1.01-1.55)。
临床怎么用
- 对轻型非心源性缺血性卒中或高危TIA患者,应尽早启动DAPT,争取在24小时内开始。
- 超过24小时启动DAPT需权衡获益与风险,尤其超过72小时可能风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dual antiplatelet therapy (DAPT) is recommended within 24 hours for patients with minor ischemic stroke or high-risk transient ischemic attack. However, the optimal timing for initiating DAPT remains unclear. METHODS: From a prospective multicenter cohort involving 20 stroke centers between January 2011 and April 2023, patients with minor noncardioembolic ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischemic attack who presented within 7 days of symptom onset were included. We evaluated outcomes based on in-hospital initiation of DAPT versus monotherapy (aspirin or clopidogrel alone). The primary outcome was a composite of recurrent stroke, myocardial infarction, and death within 90 days. Patients were grouped by time from symptom onset to hospital arrival: 0 to 24 hours, 24 to 72 hours, and >72 hours. Time-to-treatment effects were analyzed using Cox proportional hazards models, with inverse probability of treatment weighting based on propensity scores. The adjusted models incorporated demographic factors, baseline clinical characteristics, vascular risk factors, stroke subtype, relevant arterial status, and prior antiplatelet use. RESULTS: Among the 41 530 patients (mean age, 66.3 years; 25 771 [62%] male), 25 112 (60.5%) received DAPT. The 90-day primary outcome occurred in 2663 (10.7%) of the DAPT group versus 1900 (11.6%) in the monotherapy group (hazard ratio, 0.82 [95% CI, 0.77-0.87]). The benefit of DAPT was most pronounced when initiated within 24 hours (hazard ratio, 0.74 [95% CI, 0.69-0.79]). No significant benefit was observed when DAPT was initiated between 24 and 72 hours (hazard ratio, 1.00 [95% CI, 0.88-1.15]), and a higher risk was suggested for initiation beyond 72 hours (hazard ratio, 1.25 [95% CI, 1.01-1.55]). Time-dependent analysis showed a benefit crossing the null at ≈42 hours. CONCLUSIONS: Early initiation of DAPT was associated with the greatest clinical benefit, consistent with current guideline recommendations. The therapeutic effect appeared to decline progressively beyond this period, with an estimated threshold around 42 hours.
引用
- Shin J, Lee KJ, Kim CK, et al. Timing of Initiation and Efficacy of Dual Antiplatelet Therapy in Minor Stroke or High-Risk TIA. Stroke. 2026. PMID: 41480685. doi:10.1161/STROKEAHA.125.053343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。